Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.75 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.45 |
| ▸ | TERF2IP | Q9NYB0 | 4/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spr-741 SCHEMBL22106115 | 1.00 | KDM1A (0.75) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Spr-741 SCHEMBL21335177 | 1.00 | KDM1A (0.75) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Spr-741 SCHEMBL19545979 | 1.00 | KDM1A (0.75) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19545834 | 0.96 | KDM1A (0.69) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19545985 | 0.94 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19545838 | 0.94 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19545596 | 0.93 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19546032 | 0.92 | KDM1A (0.72) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL17992355 | 0.92 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19546019 | 0.92 | KDM1A (0.70) | KDM1ARCOR1SSTR5SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044654-A2 | PARENTERAL COMPOSITIONS OF ZILEUTON AND METHODS OF USE | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-02-29 | — | — | WO | claimed |
| US-20230013669-A1 | Antibacterial Treatment Using a Cannabinoid and an Active Agent | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-01-19 | — | — | US | claimed |
| CN-115066234-A | Antibacterial treatment using cannabinoids and active agents | 博塔尼克斯药物有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | claimed |
| EP-3947417-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2022-02-09 | — | — | EP | claimed |
| US-12472225-B2 | Compound for the treatment of the hemolytic-uremic syndrome | Alma Mater Studiorum—Universita' di Bologna (IT) | 2025-11-18 | — | — | US | disclosed |
| US-20250305023-A1 | MEASUREMENT OF PERMEATION OF SMALL MOLECULES INTO GRAM NEGATIVE BACTERIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2025-10-02 | — | — | US | disclosed |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2025-07-31 | — | — | US | disclosed |
| US-12370184-B2 | Antibiotic combination therapies | BioVersys AG (CH) | 2025-07-29 | — | — | US | disclosed |
| EP-3955903-B1 | SMALL-MOLECULAR ADJUVANTS AND IMPLEMENTATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2025-06-25 | — | — | EP | disclosed |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| WO-2024234082-A1 | GUANIDINYLATED AMPHIPHILIC TOBRAMYCIN DERIVATIVES AND B-LACTAM/B-LACTAMASE INHIBITOR COMBINATIONS FOR TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTIONS | UNIVERSITY OF MANITOBA (CA) | 2024-11-21 | — | — | WO | disclosed |
| US-20220184048-A1 | ANTIBIOTIC COMBINATION THERAPIES | BioVersys AG (CH) | 2022-06-16 | — | — | US | disclosed |
| CN-114569588-A | Chlorhexidine-vancomycin cooperative targeting antibacterial application | 湖南大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3969461-A1 | HOMODIMERIC TOBRAMYCIN ADJUVANT REPURPOSES NOVOBIOCIN AS AN EFFECTIVE ANTIBACTERIAL AGENT AGAINST GRAM-NEGATIVE BACTERIA | University of Manitoba (CA) | 2022-03-23 | — | — | EP | disclosed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3947417-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20190209645-A1 | POTENTIATION OF ANTIBIOTIC ACTIVITY BY A NOVEL CATIONIC PEPTIDE, SPR741 | SPERO POTENTIATOR, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190192618-A1 | SPR741 HUMAN PHARMACOKINETICS AND EFFICACIOUS DOSE | SPERO POTENTIATOR, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184048-A1 | ANTIBIOTIC COMBINATION THERAPIES | ATF4, AMPD3, CFB | KDM1A 4585/4885RCOR1 1952/4885SSTR5 4340/4885 |
| US-20190209645-A1 | POTENTIATION OF ANTIBIOTIC ACTIVITY BY A NOVEL CATIONIC PEPTIDE, SPR741 | MRPL21, VIP, NRDC | KDM1A 3098/4885RCOR1 1020/4885SSTR5 2610/4885 |
| US-20190192618-A1 | SPR741 HUMAN PHARMACOKINETICS AND EFFICACIOUS DOSE | CD74, SELPLG, SLC47A1 | KDM1A 3500/4885RCOR1 4203/4885SSTR5 2976/4885 |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | KDM1A 3918/4885RCOR1 4805/4885SSTR5 2803/4885 |
| US-12370184-B2 | Antibiotic combination therapies | ATF4, AMPD3, CFB | KDM1A 4585/4885RCOR1 1952/4885SSTR5 4340/4885 |
| US-12472225-B2 | Compound for the treatment of the hemolytic-uremic syndrome | DOHH, DHRS9, HDHD5 | KDM1A 4244/4885RCOR1 2980/4885SSTR5 612/4885 |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4412/4885RCOR1 3851/4885SSTR5 4856/4885 |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885SSTR5 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.